Immunotherapy firm Cell Medica has been granted orphan drug status in the USA for its drug to treat rare lymphomas.
The cancer immunotherapy referred to as CMD-003 is under development for Epstein-Barr Virus positive non-Hodgkin lymphomas.
CMD-003 is produced from patient immune cells taken from a blood sample and sent to the Company’s manufacturing site for activation and expansion through a proprietary procedure developed for commercial-scale use.
More than 250 patients with research prototypes of CMD-003 and has reported promising clinical results across a range of malignancies.
Meanwhile, treatment of the first patient in the CITADEL Phase II clinical trial investigating the safety and efficacy of CMD-003 for the treatment of aggressive extranodal NK/T cell lymphoma (ENKTCL) in patients who have failed previous therapies has commenced.
